Short‐Term Efficacy and Safety of Extended‐Release Fluvastatin in a Large Cohort of Elderly Patients
Authors:
- 1 July 2003
- journal article
- clinical trial
- Published by Wiley in The American Journal of Geriatric Cardiology
- Vol. 12 (4) , 225-231
Abstract
The efficacy and safety of lipid‐lowering agents in elderly individuals have not been extensively assessed. This population generally takes more drugs concurrently than middle‐aged patients, and are therefore at higher risk of drug‐drug interactions. This large‐scale, randomized, double‐blind, placebo‐controlled study investigated the efficacy and safety of extended‐release (XL) fluvastatin 80 mg once daily for up to 1 year in elderly patients with primary hypercholesterolemia. A total of 1229 patients (mean age, 75.5 years) were randomized. After 2 months of treatment, fluvastatin XL 80 mg significantly decreased plasma lipid levels from baseline compared with placebo; fluvastatin reduced total cholesterol by 25% compared with a decrease of 2.5% in the placebo group, low‐density lipoprotein cholesterol was −33% vs. −2.5%, respectively, and triglycerides were −13.3% vs. 2.9%, respectively (pKeywords
This publication has 24 references indexed in Scilit:
- Premature discontinuation of clinical trial for reasons not related to efficacy, safety, or feasibilityCommentary: Early discontinuation violates Helsinki principlesBMJ, 2001
- Comparison of the Efficacy and Tolerability of fluvastatin extended-release and immediate-release formulations in the treatment of primary hypercholesterolemia: a randomized trialClinical Therapeutics, 2001
- Clinical Pharmacokinetics of FluvastatinClinical Pharmacokinetics, 2001
- The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatmentAtherosclerosis, 1999
- Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsNew England Journal of Medicine, 1998
- Elderly patients with hypercholesterolaemiaCoronary Artery Disease, 1998
- The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol LevelsNew England Journal of Medicine, 1996
- Risk factors of coronary heart disease and total mortality among elderly men with and without preexisting coronary heart diseaseJACC, 1995
- Prevention of Coronary Heart Disease with Pravastatin in Men with HypercholesterolemiaNew England Journal of Medicine, 1995
- Effect of fluvastatin on intermediatedensity Lipoprotein (remnants) and other lipoprotein levels in hypercholestarolemiaThe American Journal of Cardiology, 1995